53 related articles for article (PubMed ID: 19524946)
21. [Prognostic factors in kidney cancer].
Patard JJ
Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
[No Abstract] [Full Text] [Related]
22. Chemotherapy of renal cell carcinoma: 1983-1989.
Yagoda A
Semin Urol; 1989 Nov; 7(4):199-206. PubMed ID: 2694257
[No Abstract] [Full Text] [Related]
23. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
Chowdhury S; Harper PG; Choueiri TK
Nat Clin Pract Oncol; 2008 Dec; 5(12):698-9. PubMed ID: 18852722
[No Abstract] [Full Text] [Related]
24. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti S; Regan M; Atkins M
BJU Int; 2008 Jun; 101 Suppl 4():31-5. PubMed ID: 18430120
[No Abstract] [Full Text] [Related]
25. Review: therapy for kidney cancer with a sarcomatoid component.
Fishman M
Clin Adv Hematol Oncol; 2011 Jan; 9(1):67-9. PubMed ID: 21326150
[No Abstract] [Full Text] [Related]
26. Renal cell carcinoma and interferon at the millennium.
Pastore RD; Pfeffer LM; Nanus DM
Cancer Invest; 2001; 19(3):281-91. PubMed ID: 11338886
[No Abstract] [Full Text] [Related]
27. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 based therapy for kidney cancer.
Dutcher JP
Cancer Treat Res; 2003; 116():155-72. PubMed ID: 14650831
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
30. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer.
Yagoda A; Bander NH
Urol Int; 1989; 44(6):338-45. PubMed ID: 2696193
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 therapy for renal cell cancer: indications, effects, and nursing implications.
Letizia M; Conway AM
Crit Care Nurse; 1996 Oct; 16(5):20-6, 30-2, 34-5. PubMed ID: 9004585
[No Abstract] [Full Text] [Related]
32. Metastatic renal cell cancer--is the outlook really improving?
Waxman J; Thomas H
Postgrad Med J; 1990 Jun; 66(776):435-40. PubMed ID: 1699216
[No Abstract] [Full Text] [Related]
33. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
Eklund JW; Kuzel TM
Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
[No Abstract] [Full Text] [Related]
34. Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2017 Feb; 14(2):76-78. PubMed ID: 28031562
[No Abstract] [Full Text] [Related]
35. UK guidelines for the systemic treatment of renal cell carcinoma.
Nathan P; Wagstaff J; Porfiri E; Powles T; Eisen T
Br J Hosp Med (Lond); 2009 May; 70(5):284-6. PubMed ID: 19451873
[TBL] [Abstract][Full Text] [Related]
36. Cell, gene and vaccine based strategies in kidney cancer.
Gitlitz BJ; Figlin RA
Cancer Treat Res; 2003; 116():183-98. PubMed ID: 14650833
[No Abstract] [Full Text] [Related]
37. Searching for the hereditary causes of renal-cell carcinoma.
Pavlovich CP; Schmidt LS
Nat Rev Cancer; 2004 May; 4(5):381-93. PubMed ID: 15122209
[No Abstract] [Full Text] [Related]
38. [DNA and microRNA microarray technologies in diagnostics and prediction for patients with renal cell carcinoma].
Slabý O; Svoboda M; Michálek J; Vyzula R
Klin Onkol; 2009; 22(5):202-9. PubMed ID: 19886357
[TBL] [Abstract][Full Text] [Related]
39. [Hereditary forms of kidney cancer and genetic screening].
Valeri A; Cussenot O
Prog Urol; 2003 Nov; 13(5 Suppl 2):1201-4. PubMed ID: 15816384
[No Abstract] [Full Text] [Related]
40. Low penetrance genetic susceptibility to kidney cancer.
Thibault F; Cancel-Tassin G; Cussenot O
BJU Int; 2006 Oct; 98(4):735-8. PubMed ID: 16978268
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
